CClinicalTrials.gg
WithdrawnNCT02528994Updated Sep 16, 2016

Short Term Dietary Serine Supplementation and Circulating Serine Levels

An interventional study of L-serine in Serine, sponsored by Massachusetts General Hospital. Withdrawn. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-16.

Sponsored by Massachusetts General Hospital · Not applicable and Interventional

Why this study was withdrawn
The PI will be leaving the institution and not continuing the study
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study will test the effect of short-term, high-dose dietary serine supplementation on circulating levels of serine. Individuals with risk factors for type 2 diabetes will be recruited into the 2 week study. Effects of dietary serine supplementation on glycemic measures will also be explored.

Read the detailed description

This is a single-center, open-label, randomized, nutritional intervention study in adults. Subjects will have three visits to the Massachusetts General Hospital Clinical Research Center (CRC) during the 2 week study.

At the first study visit (Visit 1), the following will occur: informed consent; medical and nutritional history assessment; blood pressure, weight and height, fasting blood draw and blood work during a 2 hr oral glucose tolerance test; explanation and instructions for completion of a 4-day food log; randomized assignment to dose of dietary serine supplementation (6g, 12g, 24g, or 48g); provide 7 days of dietary serine supplements; take first dose of supplement with snack; schedule Visit 2 and Visit 3.

Between Visit 1 and Visit 2, participants will complete the Food Log and take the assigned dose of dietary serine supplementation 3 times daily.

Visit 2 will occur 7 days after Visit 1. Subjects will not take dietary serine supplementation prior to Visit 2 activities. At Visit 2, the following will occur: weight and blood pressure; fasting blood draw; administration of assigned dose of dietary serine supplementation with snack after blood work; review of the 4-day food log; provide 7 days of dietary serine supplements completion of anonymous survey to assess tolerability of supplement. Participants will continue to take the assigned dose of dietary serine supplementation 3 times daily between Visit 2 and Visit 3.

Visit 3 will occur 7 days after Visit 2. At Visit 3, the following will occur: weight and blood pressure; review of the 4-day food log; fasting blood draw and blood work during a 2 hr oral glucose tolerance test; completion of study survey to assess tolerability of the supplement.

02

Conditions studied

  • Serine

Keywords

  • Dietary supplements
  • Metabolism
03

In context

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • risk factors for type 2 diabetes

Exclusion criteria

Exclusion Criteria:

  • known type 2 diabetes
  • women who are pregnant, nursing, or not using contraception or abstinence
  • taking amino acid supplements during the study or at any time 1 month prior to enrollment in the study
  • conditions causing intestinal malabsorption, including celiac disease or a history of intestinal or gastric bypass surgery
  • known active liver disease
  • currently taking or intending to take during the study duration any medication known to affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones
  • participation in any other interventional study during the study duration
  • inability to adhere to study protocol.
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Serine 6g daily

    Randomized participants will take 6g daily of dietary serine supplement

    Dietary Supplement: L-serine

  • Experimental
    Serine 12g daily

    Randomized participants will take 12g daily of dietary serine supplement

    Dietary Supplement: L-serine

  • Experimental
    Serine 24g daily

    Randomized participants will take 24g daily of dietary serine supplement

    Dietary Supplement: L-serine

  • Experimental
    Serine 48g daily

    Randomized participants will take 48g daily of dietary serine supplement

    Dietary Supplement: L-serine

Interventions

  • Dietary supplementL-serine

    Participants will take dietary serine supplementation daily

06

What researchers measure

Primary outcomes

  1. Circulating serine levels

    We will measure circulating serine levels after 14 days of intervention

    Time frame: 14 days

Secondary outcomes

  1. Supplement tolerability

    We will assess tolerability of dietary serine supplements after 14 days of intervention

    Time frame: 14 days

  2. Fasting and post-prandial glucose

    We will assess fasting and post-prandial glucose after 14 days of intervention

    Time frame: 14 days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02528994
Lead sponsor
Massachusetts General Hospital
Responsible party
Geoffrey Walford, MD (Physician, Massachusetts General Hospital) — Principal investigator
First posted
Aug 19, 2015
Start date
Sep 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Sep 16, 2016

Study contacts

Geoffrey A Walford, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion